BC Extra | Sep 22, 2017
Company News

Management tracks: Unity, Shield, Tusk

Anti-aging company Unity Biotechnology Inc. (San Francisco, Calif.) hired Bob Goeltz as CFO, Doug Rich as SVP of operations and Tamara Tompkins as general counsel. Goeltz will replace interim CFO John Smither, and Tompkins will...
BC Innovations | Aug 11, 2017
Strategy

The flip-side of immunotherapy

In the smaller print of last week’s deal between IFM Therapeutics Inc. and Bristol-Myers Squibb Co. was the latest example of a growing trend of companies aiming to draw extra value out of a cancer...
BC Week In Review | Jun 9, 2017
Clinical News

Prima reports response data from Phase IIb of IMP321 in breast cancer

Prima BioMed Ltd. (ASX:PRR; NASDAQ:PBMD) reported additional data from 15 evaluable patients with hormone receptor-positive metastatic breast cancer in the open-label portion of the European Phase IIb AIPAC trial showing that IMP321 plus paclitaxel led...
BC Week In Review | Apr 27, 2017
Clinical News

IMP321: Ph I TACTI-mel ongoing

An independent DSMB recommended continuation of the open-label, Australian Phase I TACTI-mel trial evaluating subcutaneous IMP321 every 2 weeks plus Keytruda pembrolizumab. The company will now begin enrollment of the third cohort of 6 patients...
BC Week In Review | Jan 13, 2017
Clinical News

IMP321: Interim Ph IIb AIPAC data

Interim data from 15 patients with hormone receptor-positive metastatic breast cancer in the open-label portion of the European Phase IIb AIPAC trial showed that 6 and 30 mg doses of subcutaneous IMP321 on days 2...
BC Week In Review | Jan 3, 2017
Clinical News

IMP321: Ph I TACTI-mel ongoing

A DSMB recommended continuation of the open-label, Australian Phase I TACTI-mel trial of subcutaneous IMP321 every 2 weeks plus Keytruda pembrolizumab after 1 mg IMP321 showed no safety concerns. The trial is evaluating 1, 6...
BC Week In Review | Apr 18, 2016
Clinical News

IMP321: Phase I/IIa data

An open-label, Swiss Phase I/IIa trial in 16 patients with metastatic melanoma showed that 5 synthetic melanoma peptides antigens plus IMP321 and montanide adjuvant led to antigen-specific CD8 T cell responses to at least 1...
BC Week In Review | Mar 7, 2016
Clinical News

IMP321: Phase IIb started

Prima began the European Phase IIb AIPAC trial of subcutaneous IMP321 on days 2 and 16 of each 4-week cycle plus IV paclitaxel on days 1, 8 and 15 vs. paclitaxel alone in about 211...
BC Extra | Mar 3, 2016
Clinical News

First EU trial begins of Chinese-made biologic

Prima BioMed Ltd. (ASX:PRR; NASDAQ:PBMD) and its manufacturing partner WuXi AppTec Co. Ltd. said a Belgian patient in the Phase IIb AIPAC trial was dosed with Prima's IMP321 -- the first time a patient in...
BC Week In Review | Feb 1, 2016
Clinical News

IMP321: Phase I started

Prima BioMed began the open-label, dose-escalation, Australian Phase I TACTI-mel trial to evaluate IMP321 in combination with Keytruda pembrolizumab in up to 24 patients. Prima BioMed Ltd. (ASX:PRR; NASDAQ:PBMD), Sydney, Australia   Product: IMP321 (formerly...
Items per page:
1 - 10 of 73
BC Extra | Sep 22, 2017
Company News

Management tracks: Unity, Shield, Tusk

Anti-aging company Unity Biotechnology Inc. (San Francisco, Calif.) hired Bob Goeltz as CFO, Doug Rich as SVP of operations and Tamara Tompkins as general counsel. Goeltz will replace interim CFO John Smither, and Tompkins will...
BC Innovations | Aug 11, 2017
Strategy

The flip-side of immunotherapy

In the smaller print of last week’s deal between IFM Therapeutics Inc. and Bristol-Myers Squibb Co. was the latest example of a growing trend of companies aiming to draw extra value out of a cancer...
BC Week In Review | Jun 9, 2017
Clinical News

Prima reports response data from Phase IIb of IMP321 in breast cancer

Prima BioMed Ltd. (ASX:PRR; NASDAQ:PBMD) reported additional data from 15 evaluable patients with hormone receptor-positive metastatic breast cancer in the open-label portion of the European Phase IIb AIPAC trial showing that IMP321 plus paclitaxel led...
BC Week In Review | Apr 27, 2017
Clinical News

IMP321: Ph I TACTI-mel ongoing

An independent DSMB recommended continuation of the open-label, Australian Phase I TACTI-mel trial evaluating subcutaneous IMP321 every 2 weeks plus Keytruda pembrolizumab. The company will now begin enrollment of the third cohort of 6 patients...
BC Week In Review | Jan 13, 2017
Clinical News

IMP321: Interim Ph IIb AIPAC data

Interim data from 15 patients with hormone receptor-positive metastatic breast cancer in the open-label portion of the European Phase IIb AIPAC trial showed that 6 and 30 mg doses of subcutaneous IMP321 on days 2...
BC Week In Review | Jan 3, 2017
Clinical News

IMP321: Ph I TACTI-mel ongoing

A DSMB recommended continuation of the open-label, Australian Phase I TACTI-mel trial of subcutaneous IMP321 every 2 weeks plus Keytruda pembrolizumab after 1 mg IMP321 showed no safety concerns. The trial is evaluating 1, 6...
BC Week In Review | Apr 18, 2016
Clinical News

IMP321: Phase I/IIa data

An open-label, Swiss Phase I/IIa trial in 16 patients with metastatic melanoma showed that 5 synthetic melanoma peptides antigens plus IMP321 and montanide adjuvant led to antigen-specific CD8 T cell responses to at least 1...
BC Week In Review | Mar 7, 2016
Clinical News

IMP321: Phase IIb started

Prima began the European Phase IIb AIPAC trial of subcutaneous IMP321 on days 2 and 16 of each 4-week cycle plus IV paclitaxel on days 1, 8 and 15 vs. paclitaxel alone in about 211...
BC Extra | Mar 3, 2016
Clinical News

First EU trial begins of Chinese-made biologic

Prima BioMed Ltd. (ASX:PRR; NASDAQ:PBMD) and its manufacturing partner WuXi AppTec Co. Ltd. said a Belgian patient in the Phase IIb AIPAC trial was dosed with Prima's IMP321 -- the first time a patient in...
BC Week In Review | Feb 1, 2016
Clinical News

IMP321: Phase I started

Prima BioMed began the open-label, dose-escalation, Australian Phase I TACTI-mel trial to evaluate IMP321 in combination with Keytruda pembrolizumab in up to 24 patients. Prima BioMed Ltd. (ASX:PRR; NASDAQ:PBMD), Sydney, Australia   Product: IMP321 (formerly...
Items per page:
1 - 10 of 73